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Modulation of the effect of PNPLA3 I148M mutation on steatosis
and liver damage by alcohol intake in patients with chronic hepatitis C
Letters to the EditorTo the Editor:
The Patatin-like phospholipase domain-containing-3 (PNPLA3)
rs738409 polymorphism, encoding for the I148M protein variant,
is a strong genetic determinant of hepatic fat accumulation and
progressive alcoholic as well as nonalcoholic steatohepatitis in
adults and children [1–4], explaining almost a quarter of cirrhosis
variability in alcoholic liver disease [5]. We and others [6,7] have
demonstrated that in patients with chronic hepatitis C (CHC), this
genetic factor inﬂuences steatosis development in nongenotype 3
patients, the progression of liver damage, and susceptibility to
develop cirrhosis and its complications [8] (Table 1).
Muller et al. have very recently replicated the association of
the PNPLA3 148M polymorphism with steatosis and cirrhosis in
an independent cross-sectional study in German patients with
CHC [9]. Interestingly, there was a signiﬁcantly higher preva-
lence of subjects who consumed a moderate, but potentially
harmful, intake of alcohol in this series than in that described
in our paper, and a distinct effect of the 148M polymorphism
on steatosis and liver damage according to the amount of daily
alcohol intake could be observed, in that homozygosity for the
148M was associated with steatosis only in abstainers, whereas
it was associated with cirrhosis only in at risk drinkers. These
data led the authors to hypothesize that PNPLA3 genotype
may exert a differential effect on liver damage according to
alcohol consumption.
As the mechanisms underpinning the detrimental effect of the
148M PNPLA3 variant in a rapidly widening range of liver dis-Table 1. Logistic regression analysis and meta-analysis results for the association o
presence of steatosis and cirrhosis according to daily alcohol intake in 819 previo
Italian CHC Ger
Steatosis OR (95% CI) OR 
Total 1.82 (1.33-2.58) n = 819 5.53
Abstainers 1.84 (1.33-2.65) n = 724 12.6
At risk drinkers 1.30 (0.49-5.83) n = 95 2.61
Cirrhosis OR (95% CI) OR 
Total 1.30 (1.01-1.66) n = 819 2.76
Abstainers 1.39 (1.06-1.81) n = 724 1.65
At risk drinkers 0.89 (0.37-1.94) n = 95 4.77
OR: odds ratio for the presence of homozygosity for the 148M PNPLA3 variant, adjusted
interval. Steatosis: grade 1–3 vs. grade 0. Cirrhosis: Ishak stage 5–6 vs. 0–4. Abstainer
Pooled estimates (OR, 95% c.i.) were calculated by the inverse variance method (ﬁxed e
for heterogeneity between studies.
1470 Journal of Hepatology 201eases is still unknown, to contribute elucidating this issue we
have now replicated the same analyses in our series of patients
subdivided according to alcohol intake, and provide a pooled esti-
mate of the effect of the 148M on the risk of steatosis and cirrho-
sis in the two combined studies.
Although the effect of PNPLA3 genotype might be more evi-
dent when considering more severe steatosis [2,7], pooled
results conﬁrm that in CHC the 148M polymorphism is associ-
ated with the presence of steatosis only in ‘‘abstainers’’ (<30 g
alcohol/day), possibly because of the confounding effect of
alcohol in moderate drinkers, but, on the contrary, is signiﬁ-
cantly associated with cirrhosis both in abstainers and in mod-
erate drinkers, and the effect seems more marked in those who
consume more than 30 g alcohol/day, as suggested by Muller
et al. [9]. Thus, as previously suggested [2], the detrimental
effect of the 148M PNPLA3 variant on the progression of liver
damage might not be limited to predisposition to steatosis
development.
The discrepant results obtained in our series, as reﬂected by the
signiﬁcant heterogeneity observed between the two studies for the
effect of at risk drinking on cirrhosis, may be due to the relatively
small number of drinkers in Italianpatients, or to other unmeasured
confounders, such as additional genetic [10] andenvironmental fac-
tors, and possibly the prevalence of occult HBV infection.
Nevertheless, these results indicate that additional studies are
warranted to analyze the interaction between even moderate
amounts of alcohol and PNPLA3 genotype in liver diseases.f PNPLA3 rs738409 SNP (I148M), under a recessive inheritance model, with the
usly described Italian patients [7] and 494 German patients [9] with CHC.
man CHC Pooled data
(95% CI) OR (95% CI)
 (1.55-19.8) n = 442 1.95 (1.43-2.67) n = 1261
 (1.48-108) n = 235 1.93 (1.38-2.69) n = 959
 (0.50-13.5) n = 207 1.67 (0.63-2.41) n = 302
(95% CI) OR (95% CI)
 (1.22-6.25) n = 605 1.38 (1.10-1.75) n = 1424
 (0.54-5.03) n = 335 1.40 (1.09-1.81) n = 1059
 (1.39-6.38) n = 270 2.20 (1.28-3.80)* n = 365
for age, sex, BMI, and, only for steatosis, viral genotype 3, as in [9]. c.i.: Conﬁdence
s: <30 g/day; at risk drinkers: P20 g/day, as in [9].
ffect model) by the Review Manager v.5 software (cochrane collaboration). ⁄p <0.05
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PNPLA3 rs738409 and ﬁbrosis progression in chronic hepatitis
C – There is more to it than just fat!
To the Editor:
The Hepatology community has seen a substantial rise in publica-
tions reporting data on genetic risk factors conferring risk to ﬁbro-
sis progression in non-alcoholic, alcoholic, and chronic hepatitis
C-related liver diseases. For long, hypothesis-driven, often sin-
gle-centre genetic case control studies have reported associations
of certain candidate genes with ﬁbrosis/cirrhosis which could not
be replicated. With genome-wide association studies (GWAS)
becoming a standard tool in translational research, novel candi-
date genes enter the stage which have been identiﬁed by system-
atic screening experiments [1]. GWAS make use of a hypothesis-
free, or rather – hypothesis-generating approach, and have the
potential to uncover genetic risk factors which had not been con-
sidered based on our previous pathophysiological understanding.
A striking example for such revelation is the gene coding for pat-
atin-like phospholipase domain containing-3 (PNPLA3; adiponu-
trin) of which a polymorphic variant (rs738409 G >C) was found
associatedwith liver fat content in a landmark GWAS [2], and sub-
sequently with progression of non-alcoholic fatty liver disease
(NAFLD) [3], and alcoholic liver disease (ALD) [4,5] by means of
Journal of Hepatology 201[9] Muller T, Buch S, Berg T, Hampe J, Stickel F. Distinct, alcohol-modulated
effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol
2011;55:732–733.
[10] Valenti L, De Feo T, Fracanzani AL, Fatta E, Salvagnini M, Arico S, et al.
Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with
susceptibility to and severity of alcoholic liver disease in Italian patients.
Alcohol Alcohol 2004;39:276–280.ct of PNPLA3 I148M mutation
age by alcohol intake
onic hepatitis C’’
candidate case control studies. The role of PNPLA3 rs738409 as a
risk factor for progressive ﬁbrosis can now be extended to chronic
hepatitis C. Only in 2011, four studies presented data on the role of
PNPLA3 rs738409 G which unanimously conﬁrm that carriage of
at least one allele increases the risk of advanced ﬁbrosis and cir-
rhosis [6–9] (Table 1). Our own data indicate that this association
is particularly evident in hepatitis C virus-infected individuals
who regularly drink alcohol as opposed to abstainers [6]. Regard-
ing the latter, PNPLA3 rs738409 G appears to modulate fat storage
in the liver by a yet unknown mechanism, possibly by interaction
of PNPLA3 with viral epitopes. Indeed, from the data presented in
published studies, it becomes clear that PNPLA3 rs738409 G nei-
ther aggravates steatosis nor ﬁbrosis in patients with genotype
3, supporting the hypothesis that mostly genotype 1-speciﬁc
interactions with PNPLA3 are involved.
In this issue of the Journal, Valenti and coworkers have
undertaken a pooled analysis of our [6] and their data [7] after
stratifying their patients into ‘‘at-risk’’ drinkers (daily alcohol con-
sumptionP20 g) and abstainers [10]. Hereby, they conﬁrm that
carriage of PNPLA3 rs738409 G is a risk factor for steatosis in
abstainers, but not in at risk drinkers, possibly due to a confound-
ing effect on steatosis by concomitant alcohol consumption. In
addition, by increasing the numbers of total cases and controls,
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